STOCKS TELEGRAPH

Tag: HTBX

  • Don’t Miss these 15 Biotechnology Value Stocks

    Biotech and Major Pharmaceuticals are back in the news with the Covid-19 Pandemic. Life science investors basically endorse developments that might decide the human race’s future, but what would invest in ‘cures’ mean from a cash flow point of view?
    On Thursday, a panel of independent health professionals voted 17-4 in support of the Food and Drug Administration(FDA), providing emergency permission to the applicant for the COVID-19 vaccine from BioNTech and Pfizer Inc.
    In other news Gilead Sciences Inc (GILD) revealed that it would buy MYR GmbH in cash for roughly EUR 1.15 billion ($1.39 billion), granting it access to the German biotech company’s therapy for extreme viral hepatitis.
    In yesterday’s trading session, the following stocks were the major key players.

    Immutep Limited (NASDAQ:IMMP) shares were trading up 163.43% at $5.69 at the time of writing on Thursday after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.

    Immutep Limited (NASDAQ:IMMP) share price went from a low point around $0.53 to briefly over $3.10 in past 52 weeks, though shares have since pulled back to $5.69. IMMP market cap has remained high, hitting $280.46M at the time of writing.

    If we look at the recent analyst rating IMMP, B. Riley FBR initiated coverage on IMMP shares with a Buy rating.

    TG Therapeutics Inc. (TGTX) stock soar by 40.85% to $41.72 after reportingpositive topline results from the ULTIMATE I & II Phase 3 studies evaluating Ublituximab Monotherapy for the treatment of patients with multiple sclerosis. The most recent rating by JP Morgan, on September 01, 2020, is at an Overweight.

    Heat Biologics Inc. (HTBX) last closed at $0.93, in a 52-week range of $0.19 to $4.30.

    Sangamo Therapeutics Inc. (NASDAQ:SGMO) Shares headed rising, higher as much as 52.98%. Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO), on December 7, 2020 declared updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. The most recent rating by BofA Securities, on September 08, 2020, is at a Buy.

    Entera Bio Ltd. (NASDAQ:ENTX) rose 8.18% after gaining more than $0.09 on Thursday following the firm revealed FDA approval of IND application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.

    Aytu BioScience Inc. (AYTU) last closed at $8.13, in a 52-week range of $3.35 to $29.90 after announcing definitive merger agreement with Neos Therapeutics, creating a combined $100M revenuespecialty pharmaceutical company.

    Amarin Corporation plc (AMRN) stock soar by 8.04% to $4.97. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Editas Medicine Inc. (NASDAQ:EDIT) Shares headed rising, higher as much as 32.15% following an announcement from the company that it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical trial of EDIT-301. The most recent rating by Wells Fargo, on December 10, 2020, is at an Overweight.

    Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) rose 9.04% after gaining more than $0.15 on Thursday.

    Akebia Therapeutics Inc. (AKBA) last closed at $2.95, in a 52-week range of $2.09 to $13.71. The firm recently revealed the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 5.37% to $7.65. The company recently announced transactions with Royalty Pharma (RPRX) and Athyrium Capital Management, LP, totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO™ (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    Acasti Pharma Inc. (NASDAQ:ACST) Shares headed rising, higher as much as 1.70%. The company on November 16, 2020 released its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020. The most recent rating by Oppenheimer, on September 01, 2020, is at a Perform.

    Ocugen Inc. (NASDAQ:OCGN) fall -1.79% after losing more than -$0.01 on Thursday after reporting that it will postpone its 2020 Annual Meeting of Stockholders to December 23, 2020.

    Inovio Pharmaceuticals Inc. (INO) last closed at $11.36, in a 52-week range of $2.42 to $33.79. The firm recently revealedthe successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. Analysts have a consensus price target of $13.71.

    Cellectar Biosciences Inc. (CLRB) stock soar by 3.47% to $2.09. The most recent rating by Oppenheimer, on July 01, 2020, is at an Outperform.

  • 18 Biotech Stocks That Are Great Options To Invest In

    18 Biotech Stocks That Are Great Options To Invest In

    The biotech industry is considered to be an attractive industry for the investor. This industry is continuously adopting new technological advancements. As time passes by every aspect of daily existence experience changes because of new technological breakthroughs and advancement in knowledge. Technology plays an important role in changing the lifestyle of humans. This technology also plays a very important role in the biotech industry.

    This technology has historically grown quickly. The biotech industry is striving to develop a treatment for complex diseases. It is anticipated that in 2021, one of the continuing trends in biotech is the continued improvement and development of drug research. The new technology help researchers to improve and assess diagnosis and treatment using medications.

    Check out the top 18 biotech companies you should add to your portfolio:

    BioLineRx Ltd. (NASDAQ: BLRX)

    BioLineRx Ltd. (NASDAQ: BLRX) shares were trading up 33.78% at $1.98 at the time of writing on Friday. BioLineRx Ltd. (NASDAQ: BLRX) share price went from a low point around $1.06 to briefly over $3.04 in the past 52 weeks, though shares have since pulled back to $1.98. BLRX market cap has remained high, hitting $39.57M at the time of writing. BioLineRx Ltd. (BLRX) has earlier announced the promising results from the ongoing GENESIS Phase III trial motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    Miragen Therapeutics Inc. (NASDAQ: MGEN)

    Miragen Therapeutics Inc. (NASDAQ: MGEN) last closed at $1.31, in a 52-week range of $0.31 to $2.27. Miragen Therapeutics Inc. (MGEN) has earlier acquired  Viridian Therapeutics, Inc. It has traded up 321.22% and traded down -42.29% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.80 and a quick ratio of 4.80. This company has a market capitalization of $79.29 million at the time of writing.

    Equillium Inc. (NASDAQ: EQ)

    Equillium Inc. (NASDAQ: EQ) stock soar by 5.83% to $6.35. The most recent rating by H.C. Wainwright, on July 14, 2020, is at a Buy. Previously, Equillium Inc. (EQ) has revealed that it has received a ‘Study May Proceed letter’ from the U.S. Food and Drug Administration (FDA) to commence a Phase 3 clinical trial, titled  EQUINOX, evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP)

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP) shares headed falling, lower as much as -3.24%. The most recent rating by Maxim Group, on June 26, 2019, is at a Buy. Titan Pharmaceuticals Inc. (TTNP) revealed the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering comprised of one share of common stock and one warrant to purchase one share of common stock.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) rose 2.34% after gaining more than $0.06 on Friday. Trevena Inc. (TRVN) has disclosed that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA). Looking at its liquidity, it has a current ratio of 16.20 and a quick ratio of 16.20. This company has a market capitalization of $381.29 million at the time of writing.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) last closed at $6.94, in a 52-week range of $1.45 to $19.39. Sorrento Therapeutics Inc. (SRNE) has earlier announced preclinical data about intravenous COVI-AMG™ (STI-2020; Affinity Matured COVI-GUARD) neutralizing antibody (nAb) in a preprint publication.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) shares headed falling, lower as much as -1.69%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) has earlier appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) fall -6.10% after losing more than -$0.64 on Friday. Inovio Pharmaceuticals Inc. (INO) announced that it is scheduled to release its third-quarter financial results of 2020 on November 9, 2020.  This company has a market capitalization of $1.76 billion at the time of writing.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) last closed at $4.92, in a 52-week range of $0.27 to $17.49. A class action has started on behalf of certain shareholders in Vaxart, Inc. It has traded up 1749.62% and traded down -71.87% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.00 and a quick ratio of 4.00. This company has a market capitalization of $580.22 million at the time of writing.

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT)

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT) stock drop by -41.64% to $2.13. The most recent rating by Cantor Fitzgerald, on April 17, 2020, is at an Overweight. Axovant Gene Therapies Ltd. (AXGT) has earlier announced program updates on Friday, October 30, 2020, at 11:30 AM Eastern time, for the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) shares headed falling, lower as much as -2.20%. The most recent rating by Needham, on November 14, 2019, is at a Buy. Akebia Therapeutics Inc. (AKBA) earlier revealed that it is scheduled to announce its financial results for the third quarter ended September 30, 2020, on November 5, 2020, before the opening of the market.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) fall -5.35% after losing more than -$3.81 on Friday. Moderna Inc. (MRNA) earlier revealed that it has been recognized as one of the global biopharmaceutical industry’s top employers in Science and ScienceCareers’ 2020 Top Employers Survey for the sixth consecutive year.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 3.45% to $1.20. The most recent rating by B. Riley Securities, on October 14, 2020, is at a Buy. Heat Biologics Inc. (HTBX) share price went from a low point around $0.19 to briefly over $4.30 in the past 52 weeks, though shares have since pulled back to $1.20. HTBX market cap has remained high, hitting $172.30 Million at the time of writing.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.26, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) revealed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock drop by -4.27% to $4.93. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) is scheduled to release its third-quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares headed rising, higher as much as 2.41%. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight. BioCryst Pharmaceuticals Inc. (BCRX) revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

    Soligenix Inc. (NASDAQ: SNGX)

    Soligenix Inc. (NASDAQ: SNGX) rose 0.59% after gaining more than $0.01 on Friday. Soligenix Inc. (SNGX) has disclosed that continued optional treatment with SGX301 across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH study.

    Scholar Rock Holding Corporation (SRRK)

    Scholar Rock Holding Corporation (SRRK) last closed at $38.90, in a 52-week range of $6.95 to $46.50. Analysts have a consensus price target of $30.00. Scholar Rock Holding Corporation (SRRK) announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.

  • 20 Trending Stocks In Biotechnology Industry That Need Your Attention

    20 Trending Stocks In Biotechnology Industry That Need Your Attention

    Biotechnology is considered to be the backbone of many industrial sectors and it makes a significant contribution to the well being of society. Every single day we saw changes in every sector as we experience advancements of knowledge and the new technological breakthroughs.  One of the industries that constantly change is the biotechnology industry.

    2020 is the year of continuous development and improvement in drug research. This industry is the leading rapidly growing sector of the economy. There are various trends in the biotechnology industry that the world should expect in the coming years such as the production of personalized medicines thanks to the advancement in genetics and continuous development and improvement in drug research.

    Let’s take a quick look at the 20 leading companies which are following new trends in the biotechnology sector:

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) shares were trading up 46.79% at $7.78 at the time of writing on Monday. Vaxart Inc. (NASDAQ: VXRT) share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.78. VXRT market cap has remained high, hitting $766.25M at the time of writing, giving it a price-to-sales ratio of more than 90.

    Vaxart Inc. has revealed that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. Vaxart Inc. also gave an update on its COVID-19 program.

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $7.75, in a 52-week range of $1.05 to $10.95. Cassava Sciences has announced the final results of a Phase 2bclinical study of Sumifilam in patients with Alzheimer’s Disease. Sumifilam is the first of a new class of drug compounds that bind to a protein called Filamin A. Cassava Sciences Inc. (SAVA) has earlier held a conference call on September 14.  Cassava Sciences Inc.’s market cap has remained high, hitting $182.51 million at the time of writing.

    Immunomedics Inc. (IMMU)

    Immunomedics Inc. (IMMU) stock soar by 97.99% to $83.65. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Gilead Sciences Inc. (NASDAQ: GILD) has earlier announced that it has decided to buy biotech company Immunomedics Inc for $21 billion. This decision will strengthen its cancer portfolio by gaining access to a promising drug.  Immunomedics Inc. (IMMU) has a total market capitalization of $19.19 billion.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares headed rising, higher as much as 17.88%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (NASDAQ: SRNE) has earlier disclosed that it has signed an exclusive license agreement with Mayo Clinic for an antibody-drug-nanoparticle albumin-bound (nab) immune complexes (ADNICs) platform targeting many types of human diseases including various solid and liquid tumors. Sorrento Therapeutics Inc. has a market cap of $1.86 billion.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) rose 13.00% after gaining more than $0.06 on Monday. Novan Provides Pipeline and Priority Development Programs Update. Novan Inc. (NOVN) gave a pipeline and priority development programs update. Novan Inc.’s share price went from a low point around $0.22 to briefly over $3.72 in the past 52 weeks, though shares have since pulled back to $0.53. Novan Inc.’s market cap has remained high, hitting $82.02 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 12.30% to $11.32. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has earlier signed a manufacturing agreement with Thermo Fisher Scientific. Thermo Fisher Scientific has signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

    Evofem Biosciences Inc. (NASDAQ: EVFM)

    Evofem Biosciences Inc. (NASDAQ: EVFM) Shares headed rising, higher as much as 11.90% after Evofem Biosciences to present data at the 2020 STD prevention Virtual Conference from Phase 2b Trial of EVO100 for prevention of Chlamydia and Gonorrhea in Women. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 9.28% after gaining more than $0.18 on Monday. iBio Inc. (AMEX: IBIO) has earlier disclosed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. iBio revealed earlier the preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute, induced anti-SARS-CoV-2 antibodies.  iBio Inc has a market capitalization of $379.31 million.

    Clovis Oncology Inc. (CLVS)

    Clovis Oncology Inc. (CLVS) last closed at $7.00, in a 52-week range of $2.93 to $17.37. CLVS has traded up 138.91% from its 52-weeks low and traded down -59.70% from its 52-weeks high. Analysts have a consensus price target of $9.00. Clovis Oncology Inc. (CLVS) has earlier announced Oral Plenary Session Presentation at the International Gynecologic Cancer Society (IGCS)digital annual global meeting.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 1.82% to $1.12. The most recent rating by ROTH Capital, on June 20, 2016, is at a Buy. Heat Biologics Inc. (HTBX) has earlier participated in a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10. Heat Biologics has also issued a key patent on combination platform therapy. Heat Biologics Inc. has a total market capitalization of $170.96 million.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) shares headed rising, higher as much as 12.82% after VBI Vaccines to present additional biomarker data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy. Its market capitalization has remained high, hitting $813.82 million.

    Dynavax Technologies Corporation (NASDAQ: DVAX)

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 13.37% after gaining more than $0.67 on Monday. Valneva and Dynavax have announced a Commercial supply agreement for Inactivated, adjuvanted COVID-19 vaccine. This is a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the opportunity to purchase up to an additional 90 million doses through 2025.

    Zosano Pharma Corporation (NASDAQ: ZSAN)

    Zosano Pharma Corporation (NASDAQ: ZSAN) last closed at $1.72, in a 52-week range of $0.41 to $2.45. Zosano Pharma Corporation (ZSAN) is scheduled to participate in a Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020. At the conference, Zosano Pharma Corporation will present the company overview. Zosano Pharma Corporation has a total market capitalization of $138.86 million at the time of writing.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) stock soar by 7.30% to $63.67. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier named Michael Millette as Managing Director, Canada effective immediately. Michael Millette has joined Moderna Inc in August 2020 as Vice President. Moderna Inc has a total market cap of $24.37 billion at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NASDAQ: NMTR) Shares headed rising, higher as much as 12.61%. 9 Meters Biopharma Inc. (NASDAQ: NMTR) is scheduled to participate in the upcoming two conferences in September including H.C. Wainwright: 22nd Annual Global Investment Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. These two conferences are scheduled to take place on September 15 and September 23, respectively.

    Ampio Pharmaceuticals Inc. (AMEX: AMPE)

    Ampio Pharmaceuticals Inc. (AMEX: AMPE) rose 10.80% after gaining more than $0.08 on Monday. Ampio Pharmaceuticals Inc. (AMPE) has revealed positive results in the early trial for intravenous Ampion treatment for COVID-19 patients on September 9, 2020. The Phase I trial was continued in the supervision of Michael Roshon, MD, Ph.D., Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) last closed at $105.80, in a 52-week range of $3.54 to $189.40. Novavax Inc. (NVAX) is scheduled to participate in the upcoming three conferences including Cantor Virtual Global Healthcare Conference, Morgan Stanley Virtual 18th Annual Global Healthcare Conference, and Leerink CyberRx Series: Vaccine Forum on September 15, 16, and 23, respectively. It has earlier participated in Citi 15th Annual BioPharma Virtual Conference, and H.C. Wainwright 22nd Annual Global Investment Conference on September 10, and 14, 2020, respectively.

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS)

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock soar by 5.50% to $2.11. The most recent rating by H.C. Wainwright, on July 01, 2020, is at a Buy. Marinus Pharmaceuticals Inc. (MRNS)has disclosed that it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE).

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.28%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (NASDAQ: ONTX) has earlier participated in two virtual events including Marcus Evans Healthcare Investment Webinar on September 10 and H.C. Wainwright 22nd Annual Global Investment Conference onSeptmerb 14. It is scheduled to participate in the 2nd Annual RAS-Targeted Drug Development Conference on September 16, 2020.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) last closed at $2.08, in a 52-week range of $0.46 to $3.68. In the past 52-weeks of trading, Trevena Inc. (TRVN) stock fluctuated between the low of $0.46 and a high of $3.68. It has moved up $352.17% from its 52-weeks low and moved down -43.48% from its 52-weeks high. Its market capitalization is $306.38 million at the time of writing.

     

  • Stocks to Watch amidst Mixed Market Sentiment

    Stocks to Watch amidst Mixed Market Sentiment

    The markets are headed for a weak start to the day this morning. On one hand, there is the optimism of an easing of trade tensions between the U.S and China. At the beginning of the week, negotiators said there was positive progress on the trade talks.

    The optimism is increased by news that China will be buying a large amount of US soya beans. The positive momentum is also increased by hopes of an end to the restrictions that have shrunk global trade, especially in service-related industries. This week the US FDA approved a COVID-19 treatment, and there are hopes that several vaccines are on the way. However, there are also fears that the effects of the pandemic run deeper. This is evident in the latest consumer data.

    According to the Consumer Confidence Index data, confidence dropped in August to its lowest in 6 years. This is a negative signal to the US economy since two-thirds of it runs on consumer spending. This mixed outlook has seen money continue to flow into big tech stocks.

    This is on the strength of these companies in their core markets. These companies also have the resources and the infrastructure to keep innovating and remain strong despite the prevailing circumstances. Despite the mixed outlook, there are several stocks that look set to start the day on a high note. Some of the big gainers pre-market that could dominate in the day are as below:

    PolyMet Mining Corporation [NYSE: PLM]

    PolyMet Mining Corporation is a top performer this morning and is up by over 700%. This follows the actualization of a 1:10 share split. The reverse share split was approved by the company’s board on the 21st of August. At the time the company stated that after the split, the total issued and outstanding shares will drop from 1,0006,997,495 to 100,699,749. The split does not negatively impact on shareholders as everyone will retain the percentage of stock they held before the reverse split.

    Immunic Inc [NASDAQ: IMUX]

    Immunic Inc is another top performer this morning and is up by 19% pre-market. This is largely a price action move, after the stock’s correction over the last few days. Several days ago, the company announced that it had dosed its first healthy volunteer in his phase 1 clinical program for its IMU-856. The company announced that in pre-clinical studies, the compound had shown a paradigm shift in treating gastrointestinal disease.

    Heat Biologics Inc [NASDAQ: HTBX]

    Heat Biologics Inc is a top performer this morning and is up by over 20%.  This comes after the company announced that it announced that it had published pre-clinical results on a COVID-19 vaccine. With the increased hopes of a COVID-19 vaccine, this stock stands to gain momentum through the day.

     

  • 3 Stocks to Watch This Morning As Hopes of a COVID-19 Vaccine Improves Market Sentiment

    3 Stocks to Watch This Morning As Hopes of a COVID-19 Vaccine Improves Market Sentiment

    The markets have regained renewed optimism and at yesterday’s close, the major indices were in the green. The S&P 500 closed higher by 0.65%, the Dow by 0.61%, and the NASDAQ by 0.71%. This follows increased hopes that there will be a COVID-19 vaccine by the end of the year. According to research by Deutsche Bank on the market sentiment of 500 market professionals worldwide, 56% of them are positive that there will be a vaccine before the end of 2020.  The sentiment is given weight by promising vaccine news from Oxford University.  The optimism around the markets has seen the value of biotech stocks working on COVID-19 vaccines rally. Most of the action in pre-market trading is happening around the following stocks.

    1. Immuron Limited [NASDAQ:IMRN]

    Immuron Limited [IMRN] is one of the top performers in pre-market trading and is up by 111.91% at the time of writing. This comes after IMRN announced that its IMM-124E, used for manufacturing digestive supplements, has been shown to have neutralizing activity against severe acute respiratory coronavirus-2.  Commenting on this development, the company CEO Dr. Dave Gentry stated that, they know SARS-CoV-2 is the cause of the influenza-like disease that affects the lungs. He added that the virus had been detected in anal swab tests even after in nasal-swab turned positive. This he added, offers leeway for an oral therapeutic approach that inhibits the virus in the gastrointestinal tract. As the world rushes to find a way out of the pandemic, this IMRN will continue to draw investor attention.

    1. Heat Biologics Inc [NASDAQ:HTBX]

    This is another active stock that is building upon its momentum in yesterday’s session. Heat Biologics Inc [HTBX] rallied to close with a gain of 47.15% yesterday and is up by 5% in pre-market trading. This comes after the company announced that the first patient had been treated in a phase-1 clinical trial test for PTX-35. This is the company’s antibody candidate for treating advanced solid tumors. HTBX stated that the trial would include 30 patients and would be testing for dosage and safety.  The trial is also well capitalized and has the support of a $15.2 million grant from the Cancer Prevention and Research Institute of Texas.  CEO, Jeff Wolf, stated that this trial was a first step towards advancing the clinical development of PTX-35. This is likely to play into this HTBX stock’s price action when the markets open.

    1. Miragen Therapeutics [NASDAQ:MGEN]

    Miragen Therapeutics [MGEN] is another big gainer in pre-market trading and is up by 21.57%. While there is no major news around MGEN at the moment, the stock is among those in the race for a COVID-19 vaccine.  A month ago, the company announced that it had received encouraging pre-clinical study for the treatment of idiopathic pulmonary fibrosis.